Serena Williams Returns as GLP-1 Debate Over Performance Enhancement Heats Up
TL;DR Summary
Serena Williams returned to competition at Queen’s Club in doubles with Victoria Mboko, signaling a potential Wimbledon run, after revealing she used GLP-1 drugs like tirzepatide and semaglutide to manage weight. The drugs are being monitored by WADA for potential performance enhancement, not banned yet, fueling a broader debate on sport's spirit versus science and how to handle such weight-loss therapies in elite sport.
- Serena Williams and the coming reckoning with GLP-1s and performance enhancement The New York Times
- The day Serena Williams returned and tennis got a hero back CNN
- Serena Williams shrugs off nerves for doubles win in return ESPN
- Anticipation, aces and plenty of smiles: Serena's return lives up to the moment WTA Tennis
- A quiet tennis event gets a loud last-minute guest: Serena Williams The Washington Post
Reading Insights
Total Reads
0
Unique Readers
28
Time Saved
10 min
vs 11 min read
Condensed
97%
2,022 → 64 words
Want the full story? Read the original article
Read on The New York Times